Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 3/20 | 0.58 |
| ▸ | CTSS | P25774 | 3/20 | 0.58 |
| ▸ | CTSK | P43235 | 3/20 | 0.58 |
| ▸ | CTSH | P09668 | 1/20 | 0.58 |
| ▸ | CXCR4 | P61073 | 5/20 | 0.58 |
| ▸ | CXCL8 | P10145 | 7/20 | 0.57 |
| ▸ | NPY1R | P25929 | 1/20 | 0.55 |
| ▸ | NPY2R | P49146 | 1/20 | 0.55 |
| ▸ | NPY4R | P50391 | 1/20 | 0.55 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.55 |
| ▸ | CALCA | P06881 | 1/20 | 0.55 |
| ▸ | GLP1R | P43220 | 2/20 | 0.54 |
| ▸ | GCGR | P47871 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13038595 | 0.92 | CXCL8 (0.60) | CTSLCTSSCTSKCTSHCXCR4 | |
| SCHEMBL13881394 | 0.91 | CXCL8 (0.60) | CTSLCTSSCTSKCTSHCXCR4 | |
| SCHEMBL13075186 | 0.86 | CTSL (0.55) | CTSLCTSSCTSKCTSHCXCR4 | |
| SCHEMBL29697149 | 0.84 | CXCR4 (0.65) | CTSLCTSSCTSKCTSHCXCR4 | |
| SCHEMBL12557079 | 0.84 | CXCL8 (0.48) | CTSLCTSSCTSKCTSHCXCR4 | |
| SCHEMBL30883231 | 0.84 | CXCR4 (0.68) | CXCR4NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL19448547 | 0.83 | CXCL8 (0.59) | CTSLCTSSCTSKCTSHCXCL8 | |
| SCHEMBL29742984 | 0.83 | CXCR4 (0.63) | CTSLCTSSCTSKCTSHCXCR4 | |
| SCHEMBL30697764 | 0.83 | CTSL (0.60) | CTSLCTSSCTSKCTSHCXCR4 | |
| SCHEMBL17327767 | 0.83 | CXCR4 (0.61) | CTSLCTSSCTSKCTSHCXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130309277-A1 | POLYMER MICELLES CONTAINING ANTHRACYCLINES FOR THE TREATMENT OF CANCER | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2013-11-21 | — | — | US | disclosed |
| US-8524784-B2 | Polymer micelles containing anthracylines for the treatment of cancer | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2013-09-03 | — | — | US | disclosed |
| US-20110142950-A1 | POLYMER MICELLES CONTAINING ANTHRACYLINES FOR THE TREATMENT OF CANCER | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2011-06-16 | — | — | US | disclosed |
| US-20100278932-A1 | POLYMER MICELLES CONTAINING SN-38 FOR THE TREATMENT OF CANCER | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100278932-A1 | POLYMER MICELLES CONTAINING SN-38 FOR THE TREATMENT OF CANCER | MUC1, MSN, SNX9 | CTSL 4151/4885CTSS 4704/4885CTSK 4657/4885 |
| US-20130309277-A1 | POLYMER MICELLES CONTAINING ANTHRACYCLINES FOR THE TREATMENT OF CANCER | TOP2B, TOP2A, ABCB4 | CTSL 2795/4885CTSS 3779/4885CTSK 3627/4885 |
| US-20110142950-A1 | POLYMER MICELLES CONTAINING ANTHRACYLINES FOR THE TREATMENT OF CANCER | ABCB4, TOP2A, ANXA5 | CTSL 2398/4885CTSS 2884/4885CTSK 3498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.